A detailed history of Rafferty Asset Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 227,771 shares of EXEL stock, worth $8.11 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
227,771
Previous 356,524 36.11%
Holding current value
$8.11 Million
Previous $8.01 Million 26.23%
% of portfolio
0.02%
Previous 0.03%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$21.96 - $27.6 $2.83 Million - $3.55 Million
-128,753 Reduced 36.11%
227,771 $5.91 Million
Q2 2024

Aug 13, 2024

SELL
$20.34 - $23.73 $1.15 Million - $1.34 Million
-56,373 Reduced 13.65%
356,524 $8.01 Million
Q1 2024

May 13, 2024

BUY
$20.17 - $23.93 $97,179 - $115,294
4,818 Added 1.18%
412,897 $9.8 Million
Q4 2023

Feb 13, 2024

BUY
$19.25 - $24.13 $104,354 - $130,808
5,421 Added 1.35%
408,079 $9.79 Million
Q3 2023

Nov 13, 2023

SELL
$19.04 - $22.74 $572,323 - $683,541
-30,059 Reduced 6.95%
402,658 $8.8 Million
Q2 2023

Aug 11, 2023

BUY
$18.17 - $20.48 $452,051 - $509,521
24,879 Added 6.1%
432,717 $8.27 Million
Q1 2023

May 11, 2023

SELL
$16.3 - $19.41 $1.69 Million - $2.01 Million
-103,546 Reduced 20.25%
407,838 $7.92 Million
Q4 2022

Feb 13, 2023

BUY
$14.96 - $17.39 $1.86 Million - $2.16 Million
124,298 Added 32.11%
511,384 $8.2 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $2.77 Million - $3.93 Million
176,621 Added 83.92%
387,086 $6.07 Million
Q2 2022

Aug 12, 2022

SELL
$17.44 - $23.16 $772,278 - $1.03 Million
-44,282 Reduced 17.38%
210,465 $4.38 Million
Q1 2022

May 13, 2022

SELL
$17.03 - $22.67 $1.06 Million - $1.4 Million
-61,966 Reduced 19.57%
254,747 $5.78 Million
Q4 2021

Feb 10, 2022

BUY
$15.84 - $21.88 $2.54 Million - $3.51 Million
160,604 Added 102.88%
316,713 $5.79 Million
Q3 2021

Nov 10, 2021

BUY
$16.3 - $21.14 $694,249 - $900,394
42,592 Added 37.52%
156,109 $3.3 Million
Q2 2021

Aug 10, 2021

SELL
$17.95 - $25.56 $531,463 - $756,780
-29,608 Reduced 20.69%
113,517 $2.07 Million
Q1 2021

May 10, 2021

BUY
$20.53 - $25.22 $1.98 Million - $2.43 Million
96,209 Added 205.07%
143,125 $3.23 Million
Q4 2020

Feb 10, 2021

SELL
$18.39 - $24.8 $816,387 - $1.1 Million
-44,393 Reduced 48.62%
46,916 $942,000
Q3 2020

Nov 13, 2020

BUY
$20.67 - $26.94 $577,829 - $753,107
27,955 Added 44.13%
91,309 $2.23 Million
Q2 2020

Aug 07, 2020

BUY
$16.46 - $27.42 $616,427 - $1.03 Million
37,450 Added 144.57%
63,354 $1.5 Million
Q1 2020

May 15, 2020

SELL
$14.46 - $21.8 $2.81 Million - $4.23 Million
-194,250 Reduced 88.23%
25,904 $446,000
Q4 2019

Feb 10, 2020

SELL
$15.15 - $18.89 $1.77 Million - $2.21 Million
-116,767 Reduced 34.66%
220,154 $3.88 Million
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $1.52 Million - $1.95 Million
85,952 Added 34.25%
336,921 $5.96 Million
Q2 2019

Aug 09, 2019

BUY
$18.93 - $24.75 $676,160 - $884,045
35,719 Added 16.59%
250,969 $5.36 Million
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $4.22 Million - $5.33 Million
215,250 New
215,250 $5.12 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.